About Silk Road Therapeutics

About company

Clinical stage company focused on rare diseases and 505b2 regulatory pathway. Our lead product SRT-001 ($200M annual revenue potential determined by independent third party) for Behcet's Disease showed very promising results at the Phase 2 proof-of-concept trial. The results of the trial were presented at American College of Rheumatology annual meeting on November 2019. On January 2020, our second product SRT-002 received a "May Proceed" letter from FDA for starting a Phase 2 proof-of-concept trial in the US.